| # | Country | Total Patents | |
|---|---|---|---|
| #1 | Canada | 3 | |
| #2 | Mexico | 3 | |
| #3 | United States | 3 | |
| #4 | WIPO (World Intellectual Property Organization) | 3 | |
| #5 | Brazil | 2 | |
| #6 | Republic of Korea | 2 | |
| #7 | China | 1 | |
| #8 | EPO (European Patent Office) | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Organic fine chemistry | |
| #3 | Biotechnology | |
| #4 | Measurement |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Heterocyclic compounds | |
| #3 | Medical preparations | |
| #4 | Analysing materials | |
| #5 | Peptides | |
| #6 | Microorganisms | |
| #7 | Measuring microorganism processes |
| # | Name | Total Patents |
|---|---|---|
| #1 | Gurney Mark | 15 |
| #2 | Singh Jasbir | 14 |
| #3 | Hategan Georgeta | 12 |
| #4 | Yu Peng | 8 |
| #5 | Zembower David | 6 |
| #6 | Zhou Nian | 5 |
| #7 | Zeller Wayne | 3 |
| #8 | Polozov Alexandre | 3 |
| #9 | Sandanayaka Vincent | 2 |
| #10 | Gurney Mark E | 2 |
| Publication | Filing date | Title |
|---|---|---|
| BRPI0516003A | compound, use in a compound or an ester, a pharmaceutically acceptable salt or a hydrate thereof, a pharmaceutical formulation, and a method for in vitro screening of selective prostanoid receptor ligands | |
| US2006019269A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | |
| US2006029546A1 | Materials and methods for identifying anti-schizophrenic agents | |
| WO02059265A2 | Human transglutaminases |